Capstone Investment Advisors
CPRX

Capstone Investment Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Capstone Investment Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,480
Closed -$284K – 1700
2026
Q1 		$284K Sell
11,480
-2,762
-19% -$65.8K ﹤0.01% 1385
2025
Q4 		$332K Buy
+14,242
New +$317K ﹤0.01% 1301
2025
Q1 		– Sell
-16,173
Closed -$338K – 1446
2024
Q4 		$338K Sell
16,173
-19,434
-55% -$418K ﹤0.01% 1447
2024
Q3 		$708K Buy
+35,607
New +$660K ﹤0.01% 1095
2024
Q2 		– Sell
-22,616
Closed -$360K – 2149
2024
Q1 		$360K Buy
+22,616
New +$341K ﹤0.01% 1730

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capstone Investment Advisors's CPRX Position: Q2 2026 in Review

Capstone Investment Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 11,480 shares — an estimated $284K sold.

Capstone Investment Advisors first reported a position in CPRX in Q1 2024 and held it in 5 quarters. The position peaked at $708K in Q3 2024. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Capstone Investment Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 11,480 Catalyst Pharmaceutical shares in Q2 2026, an estimated $284K.
  • Capstone Investment Advisors first reported a position in Catalyst Pharmaceutical in Q1 2024 and held it in 5 quarters.
  • Capstone Investment Advisors's Catalyst Pharmaceutical position peaked at $708K in Q3 2024.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.